ScholarLens Back to search
2019•Chinese Journal of AsthmaRequires access

Research advances of tigecyline in the treatment of multidrug-resistant Acinetobacter infection

Wei Zhang

Open publisher page 0 citations

Abstract

Acinetobacter baumanii is one of the most common causes of nosocomial infection in our country.With the extensive use of broad-spectrum antibiotics in recent years, the infection rate of multidrug-resistant acinetobacter (MDR-AB) is increasing year by year.As a new generation of glycyl tetracycline antibiotic, its antimicrobial spectrums are wide.And it overcomes the drug resistance mechanism which previous tetracycline drugs have.Especially, it has the high sensitivity to the clinical multidrug-resistant bacteria, which has become the priority choice for the treatment of MDR-AB.This article reviews the current research progress of tigocycline in the treatment of MDR-AB infection in order to provide help for its prevention and treatment. Key words: Acinetobacter baumannii; Infection; Tigecyline; Thercpeutic uses

About this research paper

What this paper is about

Acinetobacter baumanii is one of the most common causes of nosocomial infection in our country.With the extensive use of broad-spectrum antibiotics in recent years, the infection rate of multidrug-resistant acinetobacter (MDR-AB) is increasing year by year.As a new generation of glycyl tetracycline antibiotic, its antimicrobial spectrums are wide.And it overcomes the drug resistance mechanism which previous tetracycline drugs have.Especially, it has the high sensitivity to the clinical multidrug-resistant bacteria, which has become the priority choice for the treatment of MDR-AB.This article reviews the current research progress of tigocycline in the treatment of MDR-AB infection in order to provide help for its prevention and treatment. Key words: Acinetobacter baumannii; Infection; Tigecyline; Thercpeutic uses

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Acinetobacter baumanii is one of the most common causes of nosocomial infection in our country.With the extensive use of broad-spectrum antibiotics in recent years, the infection rate of multidrug-resistant acinetobacter (MDR-AB) is increasing year by year.As a new generation of glycyl tetracycline antibiotic, its antimicrobial spectrums are wide.And it overcomes the drug resistance mechanism which previous tetracycline drugs have.Especially, it has the high sensitivity to the clinical multidrug-resistant bacteria, which has become the priority choice for the treatment of MDR-AB.This article reviews the current research progress of tigocycline in the treatment of MDR-AB infection in order to provide help for its prevention and treatment. Key words: Acinetobacter baumannii; Infection; Tigecyline; Thercpeutic uses

Key concepts: Medicine, Acinetobacter, Multiple drug resistance, Tetracycline, Acinetobacter baumannii, Antibiotics, Antimicrobial, Drug resistance

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Research advances of tigecyline in the treatment of multidrug-resistant Acinetobacter infection — Research Paper | ScholarLens